These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 35813727)

  • 1. A Nomogram model for predicting the occurrence of no-reflow phenomenon after percutaneous coronary intervention using the lncRNA
    Hu CK; Cai RP; He L; He SR; Liao JY; Su Q
    J Thorac Dis; 2022 Jun; 14(6):2158-2168. PubMed ID: 35813727
    [TBL] [Abstract][Full Text] [Related]  

  • 2. LncRNA MALAT1 functions as a biomarker of no-reflow phenomenon in ST-segment elevation myocardial infarction patients receiving primary percutaneous coronary intervention.
    Yang X; Dai R; Qin Z; Cai R; Xu Y; Su Q
    Sci Rep; 2022 Feb; 12(1):3294. PubMed ID: 35228564
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Relationship between circulating miRNA-30e and no-reflow phenomenon in STEMI patients undergoing primary coronary intervention.
    Su Q; Ye Z; Sun Y; Yang H; Li L
    Scand J Clin Lab Invest; 2018 Jul; 78(4):318-324. PubMed ID: 29703083
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A nomogram risk prediction model for no-reflow after primary percutaneous coronary intervention based on rapidly accessible patient data among patients with ST-segment elevation myocardial infarction and its relationship with prognosis.
    Liu Y; Ye T; Chen K; Wu G; Xia Y; Wang X; Zong G
    Front Cardiovasc Med; 2022; 9():966299. PubMed ID: 36003914
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A nomogram for predicting the risk of no-reflow after primary percutaneous coronary intervention in elderly patients with ST-segment elevation myocardial infarction.
    Yang L; Cong H; Lu Y; Chen X; Liu Y
    Ann Transl Med; 2021 Jan; 9(2):126. PubMed ID: 33569428
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Construction and evaluation of nomogram model for individualized prediction of risk of major adverse cardiovascular events during hospitalization after percutaneous coronary intervention in patients with acute ST-segment elevation myocardial infarction.
    Fang C; Chen Z; Zhang J; Jin X; Yang M
    Front Cardiovasc Med; 2022; 9():1050785. PubMed ID: 36620648
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Predictors of no-reflow phenomenon following percutaneous coronary intervention for ST-segment elevation myocardial infarction.
    Aggarwal P; Rekwal L; Sinha SK; Nath RK; Khanra D; Singh AP
    Ann Cardiol Angeiol (Paris); 2021 Jun; 70(3):136-142. PubMed ID: 33962782
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The Value of Pre-Infarction Angina and Plasma D-Dimer in Predicting No-Reflow After Primary Percutaneous Coronary Intervention in ST-Segment Elevation Acute Myocardial Infarction Patients.
    Zhang H; Qiu B; Zhang Y; Cao Y; Zhang X; Wu Z; Wang S; Mei L
    Med Sci Monit; 2018 Jul; 24():4528-4535. PubMed ID: 29961077
    [TBL] [Abstract][Full Text] [Related]  

  • 9. In-Hospital Peak Glycemia in Predicting No-Reflow Phenomenon in Diabetic Patients with STEMI Treated with Primary Percutaneous Coronary Intervention.
    Liu F; Huang R; Li Y; Zhao S; Gong Y; Xu Z
    J Diabetes Res; 2021; 2021():6683937. PubMed ID: 33506051
    [TBL] [Abstract][Full Text] [Related]  

  • 10. MELD-XI score predict no-reflow phenomenon and short-term mortality in patient with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention.
    Zhang XT; Lin ZR; Zhang L; Zhao ZW; Chen LL
    BMC Cardiovasc Disord; 2022 Mar; 22(1):113. PubMed ID: 35300593
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evaluation of related factors, prediction and treatment drugs of no-reflow phenomenon in patients with acute ST-segment elevation myocardial infarction after direct PCI.
    Li H; Fu DG; Liu FY; Zhou H; Li XM
    Exp Ther Med; 2018 Apr; 15(4):3940-3946. PubMed ID: 29563988
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Predictive value of admission red cell distribution width-platelet ratio for no-reflow phenomenon in acute ST segment elevation myocardial infarction undergoing primary percutaneous coronary intervention.
    Celık T; Balta S; Demır M; Yıldırım AO; Kaya MG; Ozturk C; Demırkol S; Unlu M; Kılıc S; Aydın İ; Iyısoy A
    Cardiol J; 2016; 23(1):84-92. PubMed ID: 26503078
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Analysis of risk factors for PCI no-reflow in coronary heart disease and construction of related prediction models.
    Zhang L; Lin J; Luo L; Liu B; Zeng X
    Am J Transl Res; 2024; 16(8):3733-3741. PubMed ID: 39262730
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Coronary artery ectasia, an independent predictor of no-reflow after primary PCI for ST-elevation myocardial infarction.
    Schram HCF; Hemradj VV; Hermanides RS; Kedhi E; Ottervanger JP;
    Int J Cardiol; 2018 Aug; 265():12-17. PubMed ID: 29731349
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The relationship between serum rheumatoid factor level and no-reflow phenomenon in patients with acute ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention.
    Quisi A; Alıcı G
    J Clin Lab Anal; 2018 Nov; 32(9):e22598. PubMed ID: 29943408
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Systemic immune-inflammation index predicts no-reflow phenomenon after primary percutaneous coronary intervention.
    Esenboğa K; Kurtul A; Yamantürk YY; Tan TS; Tutar DE
    Acta Cardiol; 2022 Feb; 77(1):59-65. PubMed ID: 33612077
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The relationship between atherogenic index of plasma and no-reflow in patients with acute ST-segment elevation myocardial infarction who underwent primary percutaneous coronary intervention.
    Süleymanoğlu M; Rencüzoğulları İ; Karabağ Y; Çağdaş M; Yesin M; Gümüşdağ A; Çap M; Gök M; Yıldız İ
    Int J Cardiovasc Imaging; 2020 May; 36(5):789-796. PubMed ID: 31919706
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [The impact of pre-primary percutaneous coronary intervention β blocker use on the no-reflow phenomenon in patients with acute myocardial infarction].
    Wang J; Chen Y; Wang C; Zhu X
    Zhonghua Xin Xue Guan Bing Za Zhi; 2014 Oct; 42(10):822-6. PubMed ID: 25547444
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A score system to predict no-reflow in primary percutaneous coronary intervention: The PIANO Score.
    Dai C; Liu M; Zhou Y; Lu D; Li C; Chang S; Chen Z; Qian J; Ge J
    Eur J Clin Invest; 2022 Feb; 52(2):e13686. PubMed ID: 34596236
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Combination therapy reduces the incidence of no-reflow after primary per-cutaneous coronary intervention in patients with ST-segment elevation acute myocardial infarction.
    Zhou SS; Tian F; Chen YD; Wang J; Sun ZJ; Guo J; Jin QH
    J Geriatr Cardiol; 2015 Mar; 12(2):135-42. PubMed ID: 25870616
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.